Concord Biotech Limited will hold its 41st Annual General Meeting on Friday, July 31, 2026, at 12:00 Noon through Video Conferencing and Other Audio-Visual Means. The company has received a notice in writing from two members proposing the candidature of Mrs. Ekta Gupta for appointment as a Director at the ensuing meeting. The resolution regarding this appointment will be included in the remote e-voting facility.

The remote e-voting period will commence on Tuesday, July 28, 2026, at 9:00 A.M. (IST) and conclude on Thursday, July 30, 2026, at 5:00 P.M. (IST). Members can attend and participate in the AGM through the VC/OAVM facility only, and those attending through this mode shall be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

The Notice of AGM along with the Annual Report 2025-26 will be sent electronically to members whose email addresses are registered with the company or depositories. A letter containing the web-link to access the documents will be sent to members whose email addresses are not registered. The documents will also be available on the company's website, the websites of BSE Limited and National Stock Exchange of India Limited, and on the website of Central Depository Services (India) Limited.

Members holding shares in demat mode can register their email addresses by contacting their respective Depository Participant or by sending an email to the company's compliance officer. The company is providing both remote e-voting and e-voting facilities during the AGM for members to cast their votes on all resolutions.

Key Meeting Details

The meeting is being held in compliance with the provisions of the Companies Act, 2013, and relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

Concord Biotech has successfully completed regulatory inspections at its Unit-II Formulation Facility, conducted by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda. The inspection took place from June 18, 2026 to June 24, 2026. This milestone strengthens the company's global manufacturing footprint and regulatory standing in key African markets.

Regulatory Inspection Details

The successful completion of these inspections underscores Concord Biotech's adherence to international pharmaceutical manufacturing and quality standards. The key details of the regulatory assessments are outlined below:

Significance of the Development

The clearance from both the Kenyan and Ugandan drug regulatory authorities reflects the company's commitment to maintaining robust quality and compliance frameworks at its formulation manufacturing unit. Approvals from the PPB and the NDA are essential for market access and product distribution in Kenya and Uganda, respectively, and are recognized as credible regulatory benchmarks within the African pharmaceutical landscape.

This successful inspection outcome at the Unit-II Formulation Facility positions Concord Biotech to strengthen its regulatory standing across key African markets, reinforcing its presence in the region's pharmaceutical sector.